Editorji is a popular short video news and information platform based in India. It was founded in 2018 by Vikram Chandra, one of India’s leading journalists, and has risen to prominence in the digital news space in a relatively short span of time. The platform is primarily designed for mobile devices, with applications available for Android and iOS.

ABOUT US:

about us editorji

Latest Video News: Editorji provides the latest news video headlines, latest videos clip from India and the World. Get all breaking news videos on Entertainment, Business, Coronavirus, Elections, Politics and more.

Latest Video News, Breaking News, Bollywood, Political, Sports, Business News | Editorji

+91 11 4035 6666 / info@editorji.com
3rd floor, Plot B, Khasara no 360, Sultanpur, New Delhi, Delhi 110030
<a title="mail to us" href="mailto:info@editorji.com">Send Feedback</a>
<a title="Contact Us" href="mailto:info@editorji.com">Contact Us</a>

REACH US

Contact for any questions, suggestions, comments, feedback or advertisement on Editorji.com, we are always looking forward to hearing from you.

Contact Us for Feedback, Suggestions and Advertising 

Editorji content is better experienced in our app.

One dose of the AstraZeneca&nbsp;Covid-19 vaccines reduces the risk of death from the disease by 80%, a study done by the&nbsp;UK govt's&nbsp;health agency shows. Public Health England has said in a statement that 'people who had a single dose of AstraZeneca vaccine were 55% protected against death, with a figure of 44% protection for a single dose of Pfizer, compared to unvaccinated people.'
The statement further added that 'combined with the protection vaccines offer against becoming a case in the first place, this is equivalent to approximately 80% protection against mortality in individuals vaccinated with a single dose of either vaccine."
It also said protection against death from the Pfizer-BioNTech vaccine rises from approximately 80% after one dose to 97% after two doses in its new analysis.
PHE has said that their study looked at new symptomatic cases of Covid-19 between December and April and people who died within 28 days of their positive test by vaccination status.&nbsp;

One shot of AstraZeneca vaccine reduces death risk by 80%: new study

One dose of the AstraZeneca&nbsp;Covid-19 vaccines reduces the risk of death from the disease by 80%, a study done by the&nbsp;UK govt's&nbsp;health agency shows. Public Health England has said in a statement that 'people who had a single dose of AstraZeneca vaccine were 55% protected against death, with a figure of 44% protection for a single dose of Pfizer, compared to unvaccinated people.'
The statement further added that 'combined with the protection vaccines offer against becoming a case in the first place, this is equivalent to approximately 80% protection against mortality in individuals vaccinated with a single dose of either vaccine."
It also said protection against death from the Pfizer-BioNTech vaccine rises from approximately 80% after one dose to 97% after two doses in its new analysis.
PHE has said that their study looked at new symptomatic cases of Covid-19 between December and April and people who died within 28 days of their positive test by vaccination status.&nbsp;

Covid-19 vaccines finally are headed for more kids. the US regulators on Monday expanded use of Pfizer's shot to those as young as 12. The US is racing to protect middle and high school students before they head back to class in the fall.
&ldquo;This is a watershed moment in our ability to fight back the Covid-19 pandemic,&rdquo; Dr. Bill Gruber, a Pfizer senior vice president, told The Associated Press.
Most Covid-19 vaccines rolling out worldwide have been authorized for adults. Pfizer's vaccine is being used in multiple countries for teens as young as 16, and Canada recently became the first to expand use to 12 and up.
The US Food and Drug Administration declared the Pfizer vaccine is safe and offers strong protection for younger teens based on testing of more than 2,000 US volunteers aged 12 to 15.

US expands Pfizer Covid-19 shot to children as young as 12

The US regulators on Monday expanded the use of Pfizer's shot to those as young as 12

Covid-19 vaccines finally are headed for more kids. the US regulators on Monday expanded use of Pfizer's shot to those as young as 12. The US is racing to protect middle and high school students before they head back to class in the fall.
The US Food and Drug Administration declared the Pfizer vaccine is safe and offers strong protection for younger teens based on testing of more than 2,000 US volunteers aged 12 to 15.
Most Covid-19 vaccines rolling out worldwide have been authorized for adults. Pfizer's vaccine is being used in multiple countries for teens as young as 16, and Canada recently became the first to expand use to 12 and up.

Covid-19 vaccines finally are headed for more kids. the US regulators on Monday expanded use of Pfizer's shot to those as young as 12. The US is racing to protect middle and high school students before they head back to class in the fall.
&ldquo;This is a watershed moment in our ability to fight back the Covid-19 pandemic,&rdquo; Dr. Bill Gruber, a Pfizer senior vice president, told The Associated Press.
Most Covid-19 vaccines rolling out worldwide have been authorized for adults. Pfizer's vaccine is being used in multiple countries for teens as young as 16, and Canada recently became the first to expand use to 12 and up.
The US Food and Drug Administration declared the Pfizer vaccine is safe and offers strong protection for younger teens based on testing of more than 2,000 US volunteers aged 12 to 15.

Pfizer and BioNTech have submitted a request for European Union drug regulators to extend the approval of their&nbsp;coronavirus vaccine to include children ages 12 to 15.This move could offer younger and less at-risk populations in Europe access to the shots for the first time.
In a statement on Friday, the two companies said their submission to the European Medicines Agency was based on an advanced study in more than 2,000 adolescents that showed the vaccine to be safe and effective. The children will continue to be monitored for longer-term protection and safety for another two years.
BioNTech and Pfizer previously had requested their emergency use authorisation with the US Food and Drug Administration also be extended to children 12-15.

Pfizer-BioNTech seek Covid-19 vaccine nod for children above 12

Pfizer and BioNTech have submitted a request for European Union drug regulators to extend the approval of their&nbsp;coronavirus vaccine to include children ages 12 to 15. This move could offer younger and less at-risk populations in Europe access to the shots for the first time.
In a statement on Friday, the two companies said their submission to the European Medicines Agency was based on an advanced study in more than 2,000 adolescents that showed the vaccine to be safe and effective. The children will continue to be monitored for longer-term protection and safety for another two years.
BioNTech and Pfizer previously had requested their emergency use authorisation with the US Food and Drug Administration also be extended to children 12-15.

Pfizer and BioNTech have submitted a request for European Union drug regulators to extend the approval of their&nbsp;coronavirus vaccine to include children ages 12 to 15.&nbsp;This move could offer younger and less at-risk populations in Europe access to the shots for the first time.
In a statement on Friday, the two companies said their submission to the European Medicines Agency was based on an advanced study in more than 2,000 adolescents that showed the vaccine to be safe and effective. The children will continue to be monitored for longer-term protection and safety for another two years.&nbsp;BioNTech and Pfizer previously had requested their emergency use authorisation with the US Food and Drug Administration also be extended to children 12-15.

The govt may have given the nod to fast track approvals for foreign produced vaccines but will not translate to immediate roll-out of sought after vaccines such as Pfizer, Moderna&nbsp;and J&amp;J. Here is why-:

Pfizer and Moderna&nbsp;both have short-term and long term supply obligations for current production of vaccines
Pfizer and Moderna have supply commitments to at least 12 countries
Pfizer has committed to deliver 200 mn doses to US by July 2021&nbsp;
500 mn Pfizer doses have been committed to the EU by end of 2021&nbsp;
Both US, EU have done a pre-payment of $2 bn, $14.95/dose respectively for the drugs
Moderna has also received $1 billion from the US to deliver 300 million doses by the end of July 2021 and 160 million doses to EU by end of 2021J&amp;J roll-out now faces hurdle due to reports of clots and pause in usage across parts of US


The Vaccine headline is masking the reality! Vaccine wait to continue for Pfizer, Moderna

Pfizer has already committed over 1 billion doses for 2021 between US and EU. Moderna&nbsp;too has contractual agreements across the globe leaving India waiting for it's turn even as approvals get fast tracked.

The Vaccine headline is masking the reality!

The govt may have given the nod to fast track approvals for foreign produced vaccines but will not translate to immediate roll-out of sought after vaccines such as Pfizer, Moderna&nbsp;and J&amp;J. Here is why-:
<ul>
<li>Pfizer and Moderna&nbsp;both have short-term and long term supply obligations for current production of vaccines</li>
<li>Pfizer and Moderna have supply commitments to at least 12 countries</li>
<li>Pfizer has committed to deliver 200 mn doses to US by July 2021&nbsp;</li>
<li>500 mn Pfizer doses have been committed to the EU by end of 2021&nbsp;</li>
<li>Both US, EU have done a pre-payment of $2 bn, $14.95/dose respectively for the drugs</li>
<li>Moderna has also received $1 billion from the US to deliver 300 million doses by the end of July 2021 and 160 million doses to EU by end of 2021 J&amp;J roll-out now faces hurdle due to reports of clots and pause in usage across parts of US</li>
</ul>

pfizer vaccines

Categories